Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity (TiTRE)

7 juillet 2026 mis à jour par: Dasman Diabetes Institute

Tirzepatide Titration to Reduce Side Effects (TiTRE) in Individuals With Obesity

The goal of this clinical trial is to determine whether a flexible, symptom-guided titration strategy for tirzepatide can reduce gastrointestinal side effects while maintaining weight-loss effectiveness in adults with obesity without diabetes. The main questions it aims to answer are:

  1. Does flexible, symptom-guided titration reduce nausea and vomiting compared with standard per-label titration?
  2. Does flexible titration achieve weight loss comparable to standard titration?

Researchers will compare standard per-label titration with a click-based, symptom-guided titration approach to assess differences in tolerability and treatment effectiveness.

Participants will:

  • Be randomly assigned to standard or flexible tirzepatide titration
  • Use a click-based dosing method that allows small dose increases based on tolerability (flexible group)
  • Attend study visits over 76 weeks for safety and outcome assessments

This study addresses the lack of evidence for individualized titration strategies in obesity treatment and aims to improve tolerability, adherence, and long-term treatment outcomes.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

Tirzepatide is an effective treatment for obesity, but gastrointestinal adverse events during dose escalation may limit tolerability and adherence. Current labeling recommends a fixed titration schedule that does not account for individual differences in symptom tolerance. Evidence supporting individualized titration strategies in obesity treatment remains limited.

This randomized clinical trial aims to evaluate whether a flexible, symptom-guided titration strategy for tirzepatide can reduce gastrointestinal side effects while maintaining weight-loss effectiveness in adults with obesity without diabetes. Participants will be randomly assigned to either standard per-label titration or a flexible, click-based titration approach that allows smaller dose increments based on individual tolerability.

Participants in the standard group will follow the approved fixed dose-escalation schedule, while participants in the flexible group will advance doses according to gastrointestinal symptom severity, with the goal of minimizing nausea and vomiting. All participants will attend study visits over 76 weeks for assessment of weight change, tolerability, safety, and treatment adherence.

This study will compare gastrointestinal tolerability and weight-loss outcomes between titration strategies and aims to inform individualized dosing approaches that may improve adherence and long-term obesity treatment outcomes.

Type d'étude

Interventionnel

Inscription (Estimé)

68

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • Koweit
      • Kuwait City, Koweit, 15462
        • Recrutement
        • Dasman Diabetes Institute
        • Chercheur principal:
          • Ebaa AlOzairi
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  1. Adults aged 18 years and older
  2. A diagnosis of obesity (BMI ≥ 27 kg/m2) at screening with self-reported unsuccessful dietary efforts to lose weight.
  3. No diagnosis of diabetes mellites.
  4. Able to understand and sign the consent form
  5. Able to undergo DEXA scan.

Exclusion Criteria:

  • 1. History of type 1 or type 2 diabetes mellites. 2. Obesity-related:

    • A self-reported change in body weight >5 kg (11 lbs) within 90 days before screening irrespective of medical records.
    • Treatment with any medication for the indication of obesity within the past 90 days before screening.
    • Previous or planned (during the trial period) obesity treatment with surgery or a weight-loss device. However, the following are allowed: (1) liposuction and/or abdominoplasty, if performed >1 year before screening; (2) lap banding, if the band has been removed >1 year before screening; (3) intragastric balloon, if the balloon has been removed >1 year before screening; or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed >1 year before screening.

    • Uncontrolled thyroid disease, defined as thyroid stimulating hormone >6.0 mIU/L or <0.4 mIU/L as measured by the central laboratory at screening.

      3. Mental health:

    • History of major depressive disorder within 2 years before screening.
    • Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder).
    • A Patient Health Questionnaire-9 score of ≥15 at screening.
    • A lifetime history of a suicidal attempt.
    • Suicidal behavior within 30 days before screening. 4. General safety:
    • Use of non-herbal Chinese medicine or other non-herbal local medicine with unknown/unspecified content within 90 days before screening.
    • Presence of acute pancreatitis within the past 180 days prior to the day of screening.
    • History or presence of chronic pancreatitis.
    • Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
    • Renal impairment measured as estimated glomerular filtration rate value of <15 mL/min/1.73 m2 as defined by KDIGO 2012 by the central laboratory at screening.
    • History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.
    • Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack within the past 60 days prior to screening.
    • Subject presently classified as being in New York Heart Association Class IV.
    • Surgery scheduled for the duration of the trial, except for minor surgical procedures, in the opinion of the investigator.
    • Known or suspected abuse of alcohol or recreational drugs.
    • Known or suspected hypersensitivity to trial product(s) or related products.
    • Previous participation in this trial. Participation is defined as signed informed consent.
    • Participation in another clinical trial within 90 days before screening.
    • Female who is pregnant, breast-feeding, or intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.
    • Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Per-label arm (Control)
Participants receive tirzepatide with dose escalation according to the manufacturer's prescribing information.
Médicament: Tirzepatide (Per-label titration)
Tirzepatide is administered by subcutaneous injection once weekly. Dose escalation follows the manufacturer's prescribing information, with advancement through labeled dose levels at prespecified intervals to the assigned maintenance dose
Expérimental: Flexible titration arm (Intervention)
Participants receive tirzepatide administered with a flexible dose escalation schedule.
Médicament: Tirzepatide (Flexible titration)
Tirzepatide is administered by subcutaneous injection once weekly. Dose escalation follows a flexible titration schedule as defined in the study protocol.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Vomiting episodes per patient assessed using the Modified Index of Nausea, Vomiting, and Retching (M-INVR)
Délai: From enrollment (at baseline) to the end of treatment at 76 weeks.

Vomiting episodes per patient will be assessed using the validated Modified Index of Nausea, Vomiting, and Retching (M-INVR). The vomiting component is administered weekly, with scores ranging from 0 (no vomiting) to 4 (severe or frequent vomiting), where higher scores indicate worse outcomes.

Vomiting burden will be summarized as:

  • Weekly vomiting severity scores based on M-INVR, and
  • An exposure-adjusted rate of vomiting episodes (episodes per patient-week), calculated by dividing the total number of reported vomiting episodes by the total duration of follow-up for each participant.

This approach accounts for differences in treatment duration and follow-up time.
From enrollment (at baseline) to the end of treatment at 76 weeks.

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence, frequency, and duration of vomiting assessed using the MASCC Antiemesis Tool - Modified Index of Nausea and Vomiting (M-INVR)
Délai: Baseline to Week 76

Vomiting is assessed weekly using the MASCC Antiemesis Tool - Modified Index of Nausea and Vomiting (M-INVR), a validated patient-reported outcome measure.

The vomiting subscale score is calculated as the sum of relevant vomiting items, with scores ranging from 0 to 16, where higher scores indicate greater incidence, frequency, and duration of vomiting (worse outcome).
Baseline to Week 76
Change in body weight
Délai: Baseline to Week 76
Absolute and percentage change in body weight from baseline.
Baseline to Week 76
Proportion of participants remaining on active study medication
Délai: Week 76
Number of participants continuing to receive active study medication at the end of the trial.
Week 76
Change in glycated hemoglobin (HbA1c)
Délai: Baseline to Week 76
Change in HbA1c from baseline.
Baseline to Week 76
Change in lean body mass assessed by dual-energy X-ray absorptiometry (DEXA)
Délai: Baseline to Week 76
Change in total lean body mass measured by dual-energy X-ray absorptiometry (DEXA).
Baseline to Week 76
Change in visceral adiposity assessed by dual-energy X-ray absorptiometry (DEXA)
Délai: Baseline to Week 76
Change in visceral adipose tissue measured by dual-energy X-ray absorptiometry (DEXA).
Baseline to Week 76
Change in fat body mass assessed by dual-energy X-ray absorptiometry (DEXA)
Délai: Baseline to Week 76
Change in total fat body mass measured by dual-energy X-ray absorptiometry (DEXA).
Baseline to Week 76
Change in Alanine Aminotransferase (ALT)
Délai: Baseline to Week 76
Change from baseline in serum alanine aminotransferase (ALT) levels in U/L, measured using standard laboratory methods.
Baseline to Week 76
Change in Aspartate Aminotransferase (AST)
Délai: Baseline to Week 76
Change from baseline in serum aspartate aminotransferase (AST) levels in U/L, measured using standard laboratory methods.
Baseline to Week 76
Change in Gamma-Glutamyl Transferase (GGT)
Délai: Baseline to Week 76
Change from baseline in serum gamma-glutamyl transferase (GGT) levels in U/L, measured using standard laboratory methods.
Baseline to Week 76
Change in Alkaline Phosphatase (ALP)
Délai: Baseline to Week 76
Change from baseline in serum alkaline phosphatase (ALP) levels in U/L, measured using standard laboratory methods.
Baseline to Week 76
Change in Fibrosis-4 (FIB-4) index
Délai: Baseline to Week 76

Change from baseline in the Fibrosis-4 (FIB-4) index, a composite score calculated as:

FIB-4 = (Age × AST) / (Platelet count × √ALT), where age is measured in years, AST and ALT in U/L, and platelet count in 10⁹/L. The FIB-4 index is reported as a unitless value, with higher values indicating greater liver fibrosis. Values typically range from approximately 0 to 10.
Baseline to Week 76
Change in Total Cholesterol
Délai: Baseline to Week 76
Change from baseline in fasting total cholesterol levels measured using standard laboratory methods.
Baseline to Week 76
Change in Low-Density Lipoprotein Cholesterol (LDL-C)
Délai: Baseline to Week 76
Change from baseline in fasting low-density lipoprotein cholesterol (LDL-C) levels measured using standard laboratory methods.
Baseline to Week 76
Change in High-Density Lipoprotein Cholesterol (HDL-C)
Délai: Baseline to Week 76
Change from baseline in fasting high-density lipoprotein cholesterol (HDL-C) levels measured using standard laboratory methods.
Baseline to Week 76
Change in Triglycerides
Délai: Baseline to Week 76
Change from baseline in fasting triglyceride levels measured using standard laboratory methods.
Baseline to Week 76
Change in estimated glomerular filtration rate (eGFR)
Délai: Baseline to Week 76
Change from baseline in estimated glomerular filtration rate (eGFR) calculated using a standard equation.
Baseline to Week 76
Change in serum creatinine
Délai: Baseline to Week 76
Change from baseline in serum creatinine measured using standard laboratory methods.
Baseline to Week 76
Change in urinary microalbumin
Délai: Baseline to Week 76
Change from baseline in urinary microalbumin concentration measured using standard laboratory methods.
Baseline to Week 76
Change in urine albumin-to-creatinine ratio (ACR)
Délai: Baseline to Week 76
Change from baseline in urine albumin-to-creatinine ratio (ACR) measured using standard laboratory methods.
Baseline to Week 76
Change in thyroid-stimulating hormone (TSH)
Délai: Baseline to Week 76
Change from baseline in serum thyroid-stimulating hormone (TSH) measured using standard laboratory methods.
Baseline to Week 76
Change in free thyroxine (free T4)
Délai: Baseline to Week 76
Change from baseline in serum free thyroxine (free T4) measured using standard laboratory methods.
Baseline to Week 76
Change in interleukin-6 (IL-6)
Délai: Baseline to Week 76
Change from baseline in circulating interleukin-6 (IL-6) concentration measured using standard laboratory methods.
Baseline to Week 76
Change in interleukin-10 (IL-10)
Délai: Baseline to Week 76
Change from baseline in circulating interleukin-10 (IL-10) concentration measured using standard laboratory methods.
Baseline to Week 76
Change in interleukin-1 receptor antagonist (IL-1Ra)
Délai: Baseline to Week 76
Change from baseline in circulating interleukin-1 receptor antagonist (IL-1Ra) concentration measured using standard laboratory methods.
Baseline to Week 76
Change in tumor necrosis factor-alpha (TNF-α)
Délai: Baseline to Week 76
Change from baseline in circulating tumor necrosis factor-alpha (TNF-α) concentration measured using standard laboratory methods.
Baseline to Week 76
Change in health-related quality of life assessed using the 36-Item Short Form Health Survey (SF-36)
Délai: Baseline to Week 76

Health-related quality of life is assessed using the 36-Item Short Form Health Survey (SF-36), a validated patient-reported outcome measure.

The SF-36 yields an overall score ranging from 0 to 100, with higher scores indicating better health-related quality of life.
Baseline to Week 76
Change in dietary intake patterns
Délai: Baseline to Week 76
Changes in macronutrient composition and total caloric intake assessed using multiple-pass 24-hour dietary recalls.
Baseline to Week 76
Incidence of adverse events and laboratory abnormalities
Délai: Baseline to Week 76
Incidence of treatment-emergent adverse events and clinically significant laboratory abnormalities.
Baseline to Week 76
Change in retinal nerve fiber layer thickness assessed by optical coherence tomography (OCT)
Délai: Baseline to Week 76
Change from baseline in retinal nerve fiber layer thickness measured by optical coherence tomography
Baseline to Week 76
Change in arterial stiffness measured by pulse wave velocity (PWV)
Délai: Baseline to Week 76
Change from baseline in arterial stiffness assessed by carotid-femoral pulse wave velocity.
Baseline to Week 76
Change in sudomotor function assessed by Sudoscan
Délai: Baseline to Week 76
Change from baseline in sudomotor function measured by electrochemical skin conductance using Sudoscan.
Baseline to Week 76
Treatment Persistence and Discontinuation
Délai: Up to 76 weeks
Treatment persistence will be assessed by the proportion of participants remaining on active study medication at week 76. Treatment discontinuation and reasons for discontinuation will be recorded throughout the study and categorized as gastrointestinal adverse events (including nausea and vomiting), other adverse events, lack of efficacy, participant preference, protocol non-adherence, loss to follow-up, pregnancy, investigator decision, or other specified reasons.
Up to 76 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dasman Diabetes Institute

Collaborateurs

University of Ulster

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

15 mai 2026

Achèvement primaire (Estimé)

15 mai 2029

Achèvement de l'étude (Estimé)

31 décembre 2029

Dates d'inscription aux études

Première soumission

19 avril 2026

Première soumission répondant aux critères de contrôle qualité

5 mai 2026

Première publication (Réel)

8 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

8 juillet 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

7 juillet 2026

Dernière vérification

1 juillet 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • RA HM-2026-06

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner